J&J seeks permission for phase-3 trial of its single-shot Covid-19 vaccine in India, import license | Latest News India - Hindustan Times
close_game
close_game

J&J seeks permission for phase-3 trial of its single-shot Covid-19 vaccine in India, import license

PTI | , New Delhi
Apr 19, 2021 11:15 PM IST

This comes close to the heels of the central government last week deciding to fast-track emergency approvals for all foreign produced coronavirus jabs that have been given a similar nod by the World Health Organization.

Multinational pharma giant Johnson & Johnson has applied to India's drug regulator seeking permission to conduct phase-3 clinical trial of its single-dose Covid-19 vaccine in India as well as import licence, sources said.

Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of doubles doses.(Reuters file photo)
Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of doubles doses.(Reuters file photo)

They said the company has sought an early meeting of the subject expert committee on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) to take a decision on its application.

Now catch your favourite game on Crickit. Anytime Anywhere. Find out how

This comes close to the heels of the central government last week deciding to fast-track emergency approvals for all foreign produced coronavirus jabs that have been given a similar nod by the World Health Organization or regulators in the United States, Europe, Britain or Japan.

Such vaccines will be given emergency use approval mandating the requirement of post-approval parallel bridging clinical trial in place of conduct of local clinical trial under the provisions of the New Drugs and Clinical Trials Rules 2019, the health ministry had said.

According to sources, Johnson & Johnson had applied on April 12 in the Global Clinical Trial Division through the Sugam online portal, instead of applying to the biological division which deals with vaccines and other biologicals.

"Due to the technicalities involved, Johnson & Johnson has resubmitted its application on Monday," a source said.

Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of doubles doses.

So far, two vaccines -- Oxford/Astrazeneca vaccine COVISHIELD manufactured by Serum Institute in India and indigenously developed COVAXIN by Bharat Biotech -- are being administered in India, while a third vaccine Sputnik V -- developed in Russia and to be imported and sold in India by Dr Reddy's Laboratories -- has also been approved by the Indian drug regulator.

The government, meanwhile, on Monday decided to expand its vaccination drive by allowing everyone above 18 years of age eligible to be vaccinated from May 1 and permitted state governments, private hospitals and industrial establishments to procure the doses directly from manufacturers.

Get World Cup ready with Crickit! From live scores to match stats, catch all the action here. Explore now!

See more

Get Current Updates on India News, Budget 2024, Weather Today along with Latest News and Top Headlines from India and around the world.

SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, June 20, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On